[Dipeptidyl peptidase IV of peripheral blood lymphocytes in patients with primary biliary cirrhosis].
Investigations concerning changes of dipeptidyl-peptidase IV-positive (DP IV+) lymphocytes in the peripheral blood (PBL) were undertaken in 22 patients with primary biliary cirrhosis (PBC) under therapy with ursodeoxycholic acid (750 mg/day). We found that after 4-8 weeks of therapy the number of DP IV+ PBL was raised from an initially low, suppressed level of 5-12% to 18-33% corresponding to the range observed in healthy subjects. Concurrently liver function parameters of the patients were significantly improved. The identity of DP IV+ CD 26+ peripheral T-cells could be shown by the combination of cytochemical DP IV-staining with the indirect immuno-fluorescence of the lymphocyte marker CD 26. These results show that the UDCA-therapy in patients with PBC has a direct effect on the immune system and a positive influence on the immuno-regulative capacity.
Adler
D
D
Medizinische Akademie Carl Custav Carus, Klinik für Innere Medizin, Abteilung für Gastroenterologie, Dresden/Bundesrepublik Deutschland.
Kürktschiev
D
D
Subat
S
S
Lehmann
H U
HU
Schentke
K U
KU
D000328:Adult; D000945:Antigens, Differentiation, T-Lymphocyte / Q000097:blood; D016516:CD4-CD8 Ratio; D018819:Dipeptidyl Peptidase 4; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000097:blood*; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000201:enzymology; D008111:Liver Function Tests; D008297:Male; D013601:T-Lymphocytes / Q000187:drug effects* / Q000201:enzymology; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D000945:Antigens, Differentiation, T-Lymphocyte; D014580:Ursodeoxycholic Acid; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D018819:Dipeptidyl Peptidase 4
Untersuchungen der Dipeptidyl-Peptidase IV peripherer Blutlymphozyten bei Patienten mit primärer biliärer Zirrhose.